ArticleThe Journal of investigative dermatology2017
Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
Article in The Journal of investigative dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review.Frontiers in immunology · 2024Pooled it
- Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.The Cochrane database of systematic reviews · 2022Pooled it
- Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.Drugs · 2026Review
- A Systematic Review of Literature: TNF-α Blockers and JAK Inhibitors for the Treatment of Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Severe Forms of Erythema Multiforme.Health science reports · 2026Review
- Necroptosis in SJS/TEN:Current issues in molecular biology · 2026Article
- Hypoxia and IL-15 Cooperate to Induce Perforin Expression by CD8 T Cells and Promote Damage to the Skin in Murine Cutaneous Leishmaniasis.The Journal of investigative dermatology · 2025Article
- Updates in the pathogenesis of SJS/TEN.Allergology international : official journal of the Japanese Society of Allergology · 2025Review
- Recent developments in the research of Stevens-Johnson syndrome and toxic epidermal necrolysis: pathogenesis, diagnosis and treatment.European journal of medical research · 2025Review
- The Potential Roles of IL-1β, IL-6, and RIPK3 in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.Diagnostics (Basel, Switzerland) · 2025Article
- Carbamazepine-induced Stevens-Johnson Syndrome: A Case Report with Review of the Literature.Current drug safety · 2025Review
- Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology.Allergy · 2025Review
- Role of pharmacogenomics for prevention of hypersensitivity reactions induced by aromatic antiseizure medications.Frontiers in pharmacology · 2025Review
- Serum Concentrations of IL-18, IL-21, IL-22, IL-23, IL-27, and IL-31 in Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Their Correlation With Disease Severity.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2025Article
- Exploring skin adverse events and mechanisms of apalutamide using data mining algorithms and network pharmacology.Frontiers in pharmacology · 2025Article
- Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management.American journal of clinical dermatology · 2024Review
- Role of neutrophil-lymphocyte ratio as a prognostic marker in SJS/TEN patients.Archives of dermatological research · 2024Article
- Severe cutaneous adverse reactions.Nature reviews. Disease primers · 2024Review
- The Role of NLRP3 Inflammasome in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.Medical research archives · 2024Article
- Case report: Toxic epidermal necrolysis as a unique presentation of acute graft versus host disease in a pediatric patient.Frontiers in immunology · 2024Article
- Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study.Frontiers in immunology · 2024Observational
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 9 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis and prognosis monitoring for Stevens-Johnson syndrome/toxic epidermal necrolysis (TEN) still remain a challenge. This study aims to explore any cytokine/chemokine with prognostic potential in Stevens-Johnson syndrome/TEN. Through screening a panel of 28 serological factors, IL-6, IL-8, IL-15, tumor necrosis factor-α, and granulysin were upregulated in patients with Stevens-Johnson syndrome/TEN and selected for the further validation in total 155 patients with Stevens-Johnson syndrome/TEN, including 77 from Taiwan and 78 from the Registry of Severe Cutaneous Adverse Reactions. Among these factors evaluated, the levels of IL-15 (r = 0.401; P < 0.001) and granulysin (r = 0.223; P = 0.026) were significantly correlated with the disease severity in 112 samples after excluding patients with insufficient data to calculate the score of TEN. In addition, IL-15 was also associated with mortality (P = 0.002; odds ratio, 1.09; 95% confidence interval, 1.03-1.14; P = 0.001; adjusted odds ratio, 1.10; 95% confidence interval, 1.04-1.16). Consistent results were obtained after the exclusion of Taiwanese patients with sepsis to rule out possible confounders. Moreover, IL-15 was shown to enhance cytotoxicity of cultured natural killer cells and blister cells from patients with TEN. Our findings highlight a usefulness of IL-15 in prognosis monitoring and therapeutic intervention of this devastating condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.